[go: up one dir, main page]

MX352904B - Compuestos de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo. - Google Patents

Compuestos de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo.

Info

Publication number
MX352904B
MX352904B MX2014005343A MX2014005343A MX352904B MX 352904 B MX352904 B MX 352904B MX 2014005343 A MX2014005343 A MX 2014005343A MX 2014005343 A MX2014005343 A MX 2014005343A MX 352904 B MX352904 B MX 352904B
Authority
MX
Mexico
Prior art keywords
compositions
cyanonaphthalen
pyridin
thio
methods
Prior art date
Application number
MX2014005343A
Other languages
English (en)
Other versions
MX2014005343A (es
Inventor
Yeh Li-Tain
D Quart Barry
Original Assignee
Ardea Biosciences Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biosciences Inc Star filed Critical Ardea Biosciences Inc Star
Publication of MX2014005343A publication Critical patent/MX2014005343A/es
Publication of MX352904B publication Critical patent/MX352904B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El ácido 2-((3-(4-cianonaftalen-1-il)piridin-4-il)tio)-2-metilprop anoico es útil en la modulación de los niveles de ácido úrico en sangre o suero. En algunas realizaciones, el ácido 2-((3-(4-cianonaftalen-1-il)piridin-4-il)tio)-2-metilpropanoico se usa en el tratamiento o prevención de trastornos relacionados con niveles anómalos de ácido úrico. En algunas realizaciones, el ácido 2-((3-(4-cianonaftalen-1-il)piridin-4-il)tio)-2-metilpropano ico se usa para reducir los niveles de ácido úrico en suero en un ser humano. En el presente documento también se describen composiciones que comprenden ácido 2-((3-(4-cianonaftalen-1-il)pir idin-4-il)tio)-2-metilpropanoico, y su uso en la modulación de los niveles de ácido úrico en sangre o suero.
MX2014005343A 2011-11-03 2012-11-02 Compuestos de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo. MX352904B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555450P 2011-11-03 2011-11-03
US201261616363P 2012-03-27 2012-03-27
PCT/US2012/063415 WO2013067425A1 (en) 2011-11-03 2012-11-02 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same

Publications (2)

Publication Number Publication Date
MX2014005343A MX2014005343A (es) 2014-09-08
MX352904B true MX352904B (es) 2017-12-13

Family

ID=47178362

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005343A MX352904B (es) 2011-11-03 2012-11-02 Compuestos de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo.

Country Status (22)

Country Link
US (2) US10047050B2 (es)
EP (2) EP3501520A1 (es)
JP (1) JP6025853B2 (es)
KR (1) KR101988066B1 (es)
CN (2) CN104023723B (es)
AU (1) AU2012332154B2 (es)
BR (1) BR112014010495A2 (es)
CA (1) CA2852490A1 (es)
DK (1) DK2776028T3 (es)
EA (1) EA026101B1 (es)
ES (1) ES2704233T3 (es)
HK (1) HK1198929A1 (es)
HU (1) HUE040625T2 (es)
IL (1) IL232105A (es)
MX (1) MX352904B (es)
MY (1) MY180138A (es)
PH (1) PH12014500997A1 (es)
PL (1) PL2776028T3 (es)
SG (1) SG11201402016PA (es)
UA (1) UA114304C2 (es)
WO (1) WO2013067425A1 (es)
ZA (1) ZA201402795B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
MX352904B (es) * 2011-11-03 2017-12-13 Ardea Biosciences Inc Star Compuestos de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo.
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
CN104292124B (zh) * 2014-09-27 2016-01-20 张远强 硝基苯基取代的萘环丁二酸酰胺衍生物、其制备方法及用途
CN104311452B (zh) * 2014-09-27 2016-01-06 张远强 腈基萘环的丁二酸酰胺衍生物、其制备方法及用途
WO2017028762A1 (zh) * 2015-08-14 2017-02-23 广东东阳光药业有限公司 一种萘环化合物的晶型
PE20181521A1 (es) * 2015-12-08 2018-09-24 Ardea Biosciences Inc Composicion farmaceutica que comprende un potente inhibidor de urat1
CN105884807A (zh) * 2016-04-26 2016-08-24 昆药集团股份有限公司 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法
CN106117130A (zh) * 2016-06-28 2016-11-16 昆药集团股份有限公司 一种2‑((3‑(4‑氰基萘‑1‑基)吡啶‑4‑基)硫基)‑2‑甲基丙酸的晶型及其制备方法和药物组合物
CN114315715B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与应用
JP7449837B2 (ja) 2020-10-09 2024-03-14 フジモリ産業株式会社 建物用煙突の継手構造

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6054310B2 (ja) 1979-02-21 1985-11-29 三井東圧化学株式会社 ピリダジン誘導体と農園芸用殺菌剤
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5051442A (en) 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
ATE142494T1 (de) 1990-11-30 1996-09-15 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
CA2105617A1 (en) 1992-09-10 1994-03-11 Yoshikazu Iwasawa Substituted acetamide derivatives
US5344651A (en) 1993-07-23 1994-09-06 The Procter & Gamble Company Cyproterone acetate thioacetate
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
US6348475B1 (en) * 2000-06-01 2002-02-19 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
GB0108339D0 (en) 2001-04-03 2001-05-23 Syngenta Participations Ag Organics compounds
JP3824899B2 (ja) * 2001-09-21 2006-09-20 株式会社ヒューマンセルシステムズ 腎臓及び胎盤型尿酸トランスポーターとその遺伝子
KR101241716B1 (ko) 2004-08-25 2013-03-08 아디아 바이오사이언스즈 인크. ＨＩＶ 역 전사 효소의 억제제로서 Ｓ-트리아졸릴 α-메르캅토아세트아닐리드
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US20070099970A1 (en) 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
US20090131384A1 (en) 2006-03-22 2009-05-21 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
NZ588374A (en) * 2008-04-30 2012-11-30 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CN102186832B (zh) 2008-09-04 2014-04-02 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
CA2760940A1 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Methods of modulating uric acid levels
CA2761335A1 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Compounds, compositions and methods for modulating uric acid levels
WO2011044140A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
SG182404A1 (en) 2010-01-08 2012-08-30 Ardea Biosciences Inc Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
US9402827B2 (en) * 2010-03-30 2016-08-02 Ardea Biosciences, Inc. Treatment of gout
LT2582683T (lt) 2010-06-15 2018-06-11 Ardea Biosciences, Inc. Podagros ir hiperuricemijos gydymas
BR112012032193A2 (pt) 2010-06-16 2019-09-24 Ardea Biosciences Inc composto, composiçoes e métodos de uso de feniltioacetato
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
MX352904B (es) 2011-11-03 2017-12-13 Ardea Biosciences Inc Star Compuestos de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo.
PE20181521A1 (es) * 2015-12-08 2018-09-24 Ardea Biosciences Inc Composicion farmaceutica que comprende un potente inhibidor de urat1

Also Published As

Publication number Publication date
PH12014500997B1 (en) 2014-08-04
HUE040625T2 (hu) 2019-03-28
HK1198929A1 (en) 2015-06-19
KR20140095078A (ko) 2014-07-31
DK2776028T3 (en) 2019-02-04
ZA201402795B (en) 2019-09-25
ES2704233T3 (es) 2019-03-15
MY180138A (en) 2020-11-23
EP2776028B1 (en) 2018-10-17
NZ623857A (en) 2016-08-26
JP2014532726A (ja) 2014-12-08
EA026101B1 (ru) 2017-03-31
WO2013067425A1 (en) 2013-05-10
EP3501520A1 (en) 2019-06-26
PL2776028T3 (pl) 2019-03-29
PH12014500997A1 (en) 2014-08-04
US10570095B2 (en) 2020-02-25
IL232105A (en) 2017-05-29
US20140256748A1 (en) 2014-09-11
EP2776028A1 (en) 2014-09-17
SG11201402016PA (en) 2014-05-29
IL232105A0 (en) 2014-05-28
AU2012332154B2 (en) 2016-11-17
CN104023723B (zh) 2017-05-31
KR101988066B1 (ko) 2019-09-27
BR112014010495A2 (pt) 2017-04-25
JP6025853B2 (ja) 2016-11-16
MX2014005343A (es) 2014-09-08
US20190135756A1 (en) 2019-05-09
US10047050B2 (en) 2018-08-14
CA2852490A1 (en) 2013-05-10
UA114304C2 (uk) 2017-05-25
EA201490795A1 (ru) 2014-09-30
CN104023723A (zh) 2014-09-03
AU2012332154A1 (en) 2014-05-01
CN106963761A (zh) 2017-07-21

Similar Documents

Publication Publication Date Title
MX352904B (es) Compuestos de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo.
UA107115C2 (uk) Тіоацетатні похідіні піридину, композиція на їх основі та їх застосування
TN2010000237A1 (en) Novel compounds and compositions and methods of use
WO2011159840A3 (en) Phenylthioacetate compounds, compositions and methods of use
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2010135530A3 (en) Compounds, compositions and methods for modulating uric acid levels
WO2010028189A3 (en) Compounds, compositions and methods of using same for modulating uric acid levels
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2010093727A8 (en) Quinazolinones as prolyl hydroxylase inhibitors
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
MX2015002289A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.
EA201000098A1 (ru) Производные хиназолинамида
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EP4327886A3 (en) Pyrimido- pyridazinone compounds and use thereof
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
MX354981B (es) Medicamento para tratamiento terapeutico y/o mejoramiento de sepsis.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
EP1888782A4 (en) MODULATION OF STAT-6 EXPRESSION FOR THE TREATMENT OF HYPERREACTIVITY OF AIRWAYS
WO2012148200A3 (ko) 허혈성 혈관 질환 치료시술 보조용 조성물
BR112013026644A2 (pt) método para a modulação da atividade de citocina
IT1399972B1 (it) Banderella mininvasiva per il trattamento chirurgico dell'incontinenza urinaria femminile da sforzo
MX2015013618A (es) Derivado de fenilo.

Legal Events

Date Code Title Description
FG Grant or registration